Books about Biotech from Amazon.com

Entrepreneur's Notebook propels you on a whirlwind tour of the start-up process. It is an invaluable reference for new and experienced entrepreneurs that includes chapters on a wide range of topics, from entrepreneurial team building to business plans to financing. This excellent book provides an incredible amount of practical information that will help you make smarter decisions and avoid costly mistakes. The author, Steven K. Gold, is an accomplished entrepreneur who has co-founded and led five early-stage ventures. As an investor and mentor, he also advises many entrepreneurs and young companies. He earned his B.S.E. in Entrepreneurial Management from the Wharton School of the University of Pennsylvania, and his M.D. from Brown University Medical School..
Price: $9.59 [Notify me when price goes down.]

This book is the first complete guide to valuation in life sciences for industry  professionals, investors, and academics Boris Bogdan and Ralph Villiger introduce the characteristics of drug and medical device development, explain how to translate these into the valuation, and provide valuable industry data. After guiding the reader through the theory of valuation, including discounted cash-flow and real options, the authors demonstrate how to value projects, patents, licences, firms and stocks on real-life examples, even treating complex licence and company structures. Special emphasis is put on the practicability of the proposed methods by including many hands-on examples, without compromising on realistic results. Ralph Villiger and Boris Bogdan have written what is sure to become the industry standard reference for valuation of pharmaceutical and biotechnology projects and companies. At a time when the healthcare industry is placing increasing emphasis on licensing and M&A as a core strategy this book provides a firm understanding of the way in which products and businesses can be valued at all stages of their development.

Dr. Martin Buckland, Chief Business Officer, Astex Therapeutics, Cambridge, UK

The book presents a number of innovative ideas, illustrated with practical examples that should improve decision-making in the drug development process, intellectual property evaluation, licensing and sublicensing. The authors make a persuasive case for the use of advanced techniques and the section on worked-examples should be particularly appealing to practitioners.

Dr. Martin Grossmann, Novartis Pharmaceuticals

There is no doubt that this book will become an essential reference tool for professionals in technology transfer, business developers and biotech companies, as well as the pharmaceutical industry and Life Science investors.

Jean-Pierre Saintouil, Director of Technology Transfer Department, Institut Pasteur, Paris, France

.
Price: $62.20 [Notify me when price goes down.]

Why has the biotechnology industry failed to perform up to expectations—despite all its promise? In Science Business, Gary P. Pisano answers this question by providing an incisive critique of the industry. Pisano not only reveals the underlying causes of biotech’s problems; he offers the most sophisticated analysis yet on how the industry works. And he provides clear prescriptions for companies, investors, and policymakers seeking ways to improve the industry’s performance.

According to Pisano, the biotech industry’s problems stem from its special character as a science-based business. This character poses three unique business challenges: 1) how to finance highly risky investments under profound uncertainty and long time horizons for R&D, 2) how to learn rapidly enough to keep pace with advances in drug science knowledge, and 3) how to integrate capabilities across a broad spectrum of scientific and technological knowledge bases.

The key to fixing the industry? Business models, organizational structures, and financing arrangements that place greater emphasis on integration and long-term learning over shorter-term "monetization" of intellectual property. Pisano maintains that all industry players—biotech firms, investors, universities, pharmaceutical companies, government regulators—can play a role in righting the industry. The payoff? Valuable improvements in health care, and a shinier future for human well-being..
Price: $12.97 [Notify me when price goes down.]

The pharmaceutical industry is extremely complex, and so are the inner workings of the pharmaceutical and biotechnology companies operating within it. Even the most seasoned industry professionals may find it difficult to understand the activities of, and interdependencies among, all key functions within a pharmaceutical company. Yet this knowledge is crucial when the responsibilities for--or repercussions of--key initiatives ripple across an organization.

Understanding Pharma is a must-read for anyone in the pharmaceutical industry--those new to the industry, industry veterans, and those working in or serving the industry.

Gain an understanding of the inner workings of each functional area in the typical pharmaceutical company

Learn the interdependencies of each functional area and how they affect the company's strategic goals

Understand how each functional area impacts the company's financial success.

Topics covered in the book include:

The global scope of the pharmaceutical industry

Typical pharmaceutical company structure

Customer groups supply and demand drivers

Pharmaceutical product lifecycle

Drug Discovery

Drug Development

Business Development

Marketing

Sales

Managed Markets

Manufacturing

Distribution

Each function-specific chapter explains:

The role of that functional area in fulfilling the pharmaceutical company s mission

The impact of that functional area on company profitability and strategic vision

Key activities within that functional area

Understanding Pharma is an ideal resource for professionals in a wide variety of careers, including:

Sales

Marketing

Market Research

Medical Affairs

Business Development

Training

Contract Research

Medical Education

Advertising

Public Relations

Students preparing for careers in the pharmaceutical industry will also find it extremely effective in orienting them to their chosen field, and the industry as a whole.

Be sure your team has what it takes to succeed in this competitive environment. Understanding Pharma will provide the practical knowledge they need. Also be sure to check out the companion book, Lingua Pharma, the first comprehensive glossary of industry-related terms..
Price: $79.74 [Notify me when price goes down.]

Widely regarded as the most innovative, successful biotech firm ever, Amgen led its industry in revenue and sales growth in 2007. Top magazines including Fortune and Industry Week have repeatedly named it one of America's best companies to work for.

In Science Lessons, Gordon Binder--CEO and chairman during 1988-2000--describes Amgen's climb to success. Revealing the highs and lows it experienced in the race to develop blockbuster drugs, he takes readers from the time Amgen had just three months of capital in the bank and no viable products in the pipeline to its spectacular success. The turning point? The 1989 launch of Epogen, which dramatically helped kidney dialysis patients suffering from debilitating anemia. Other landmark drugs, including Neupogen, would follow.

Through engaging anecdotes and cogent insights, Binder weaves a fascinating tale while offering his unique brand of practical management advice. Using the principals of the scientific method, he shares his recommendations for tackling pressing business challenges--such as managing creative employees, navigating the IPO process, and protecting intellectual property.

This colorful first-person account showcases the visionary science and daring business strategy that made Amgen great--offering valuable lessons for all companies..
Price: $12.95 [Notify me when price goes down.]

A riveting tale of the battle over genetically engineered foods, and an inside look at a biotech food empire. Ultimately a story of idealism, and conflicting dreams about the shape of a better world. Softcover .
Price: $7.79 [Notify me when price goes down.]

Recipient of a Silver Medal for science writing in the 2007 Independent Publishers Book Awards, INTERVENTION challenges two of the most sacred tenets of modern society, innovation and technology, from the perspective of the unique risks they present. Using genetic engineering as its model, it paints a vivid picture of the scientific uncertainties that biotech risk evaluations dismiss or ignore, and lays bare the power and money conflicts between academia, industry and regulators that have sped these risky innovations to the market. 'Intervention' champions an alternative method for assessing the risks of technology, developed by the world's top risk experts, that can eliminate such conflicts, help regain public trust in science and government, and drive research and development toward more useful, safer products..
Price: $10.00 [Notify me when price goes down.]

It's the technology of the posthuman age: biotech! Upgrade your old body with smart drugs and viral nano . . . or improve on nature with eugenics and gene-fixing. But it's not just about the future. GURPS Bio-Tech includes a full range of historical and modern medical equipment, from early vaccines to surgical robots, along with game stats for the world's most deadly diseases.

GURPS Bio-Tech also includes a complete set of character templates for bio-tech professions, rules for biotech magic, and two original campaign settings.

Say goodbye to your old body. Have you upgraded your genetics this year?

GURPS Fourth Edition supplement..
Price: $17.95 [Notify me when price goes down.]

For most people, the global war over genetically modified foods is a distant and confusing one. The battles are conducted in the mystifying language of genetics.

A handful of corporate "life science" giants, such as Monsanto, are pitted against a worldwide network of anticorporate ecowarriors like Greenpeace. And yet the possible benefits of biotech agriculture to our food supply are too vital to be left to either partisan.

The companies claim to be leading a new agricultural revolution that will save the world with crops modified to survive frost, drought, pests, and plague. The greens warn that "playing God" with plant genes is dangerous. It could create new allergies, upset ecosystems, destroy biodiversity, and produce uncontrollable mutations. Worst of all, the antibiotech forces say, a single food conglomerate could end up telling us what to eat.

In Food, Inc., acclaimed journalist Peter Pringle shows how both sides in this overheated conflict have made false promises, engaged in propaganda science, and indulged in fear-mongering. In this urgent dispatch, he suggests that a fertile partnership between consumers, corporations, scientists, and farmers could still allow the biotech harvest to reach its full potential in helping to overcome the problem of world hunger, providing nutritious food and keeping the environment healthy.

.
Price: $5.27 [Notify me when price goes down.]

Arguing that we are on the verge of a revolution of unparalleled impact, the author makes an impassioned plea for awareness of the environmental, commercial and moral implications of biotechnology. Developments in genetic engineering will have a profound effect on our lives, but at what cost?.
Price: $0.36 [Notify me when price goes down.]